We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

HPV Vaccine Appears Safe in Early Pregnancy

By HospiMedica International staff writers
Posted on 14 Apr 2017
A new study suggests that vaccination against human papillomavirus (HPV) during pregnancy does not increase the risk of maternal or fetal complications.

Researchers at the Danish Statens Serum Institut conducted a retrospective study of all women in Denmark who had a pregnancy that ended between October 1, 2006, and November 30, 2013. Using nationwide registers, the researchers linked data on quadrivalent HPV vaccination, adverse pregnancy outcomes, and potential confounders. Vaccinated women were matched on a 1:4 ratio with women who were not. Study outcomes included a range of gestational and newborn factors.

The results revealed 65 birth defects in vaccine-exposed pregnancies, compared to 220 in unexposed pregnancies; 20 spontaneous abortions with vaccine exposure versus 131 without; 116 preterm births versus 407; 76 cases of low birth weight versus 277; 171 cases of small size for gestational age versus 783; and two stillbirths versus four. Upon analysis, exposure to HPV vaccine was not associated with significantly higher risks for major birth defect, spontaneous abortion, preterm birth, low birth weight, small size for gestational age, or stillbirth. The study was published on March 30, 2017, in the New England Journal of Medicine (NEJM).

“Our results are consistent with other evidence that does not indicate that the vaccination of pregnant women with inactivated virus, bacterial, or toxoid vaccines generally confers a higher risk of adverse pregnancy outcomes than no such vaccination,” concluded lead author Nikolai Scheller, MD, and colleagues. “Our results also confirm and considerably expand on results from previous studies of the quadrivalent HPV vaccine.”

Introduced in 2006, the quadrivalent HPV vaccine covers the four viral strains most closely associated with gynecologic cancer (HPV-6, 11, 16, and 18). HPV types 6 and 11 also cause genital warts. As of 2014, 58 countries include HPV in their routine vaccinations for all girls around the ages of 9-13, and some countries vaccinate boys as well; the vaccines provide protection for at least eight years. Denmark also vaccinates women up to 26 years of age, and as a result some women are inadvertently exposed to HPV vaccination during early pregnancy.

Gold Member
CPAP Ventilator
Somnus DM18
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Mammography System (Analog)
MAM VENUS

Channels

Critical Care

view channel
Image: Indocyanine green (ICG) lymphography in acute heart failure patients (Ponikowska B. et al., Eur J Heart Fail (2025), DOI: 10.1002/ejhf.3655)

Faster Lymph Flow Predicts Better Response to Diuretics in Acute Heart Failure

Heart failure is a serious condition in which the heart cannot pump enough blood to meet the body’s needs, often causing dangerous fluid buildup and swelling. Although diuretics are the primary treatment... Read more

Surgical Techniques

view channel
Image: Using a laser wavelength that matches the collagen absorption peak allows selective ablation of PDAC without harming healthy tissue (Photo courtesy of Houkun Liang/Sichuan University)

Laser-Based Technique Eliminates Pancreatic Tumors While Protecting Healthy Tissue

Pancreatic ductal adenocarcinoma (PDAC) is the most common and deadliest form of pancreatic cancer, ranking as the third leading cause of cancer-related deaths worldwide. Current tumor ablation techniques—using... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more